Contact
Please use this form to send email to PR contact of this press release:
Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
TO:
Please use this form to send email to PR contact of this press release:
Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
TO: